On-Demand Learning

Patent

Past 3 Months

Transcripts

Recorded on: Apr. 17, 2013

JOSE ESTEVES: OK. We're going to get started here. We've got our second to last panel. And for this panel, we're going to be discussing patent monetization and the current environment. And we're lucky to have three panelists here with us. First, we have, in alphabetical order, we've got Abha Divine. Abha is Managing Director and Founder of Techquity Capital Management. Abha's career demonstrates proven results in the successful planning and launch ...

Recorded on: Apr. 17, 2013

JOSE A. ESTEVES: OK. We're going to go ahead and get started with the afternoon portion of the program. [SIDE CONVERSATION] JOSE A. ESTEVES: Yes. [SIDE CONVERSATION] JOSE A. ESTEVES: All right. So we've got the first of three panels of the afternoon program. And in this panel we're going to have presentations exploring new and emerging models related to patent monetization. And we have four speakers lined up for you. Our first is Cheryl Malone. ...

Recorded on: Apr. 17, 2013

JOSE A. ESTEVES: OK. We're gonna go ahead and get started. So our presenter for the next hour is Joe Yang. And he will be talking about developments in patent law that impact patent monetization. Joe is a partner at PatentEsque Law Group, LLP, where he specializes in the use of patents as business assets. He handles all types of IP transactions and has served as an arbitrator. He previously served as VP and general counsel of Cryptographic Research, ...

Recorded on: Apr. 17, 2013

JOSE A. ESTEVES: So to keep things moving, while our panelists take their place, I'm going to start with the introductions for our last panel. And our last panel is going to try to take things up a little bit higher, and talk about themes and issues affecting patent monetization. Our speakers, in alphabetical order, are Robert Aronoff. Robert is a Managing Partner at Pluritas, LLC. He is also the founder of Pluritas, which is a leading Intellectual ...

Recorded on: Apr. 3, 2013

SCOTT A. MCKEOWN: So continuing on. And Dave's a tough act to follow, but again we're very happy to have him here. I think we got the benefit of both the PTO slides and Dave's insight, which is great. So tough act to follow. So what I want to do in this next hour is a little bit just try to pull everything together in terms of the mechanics of these procedures. And I'm not going to get into the mechanics too much other than at a very high level, ...

Recorded on: Apr. 3, 2013

SCOTT: Welcome back, everybody. We're going to get started so we can get everybody to lunch on time. So the next module is focusing on discovery, which is a new component of these PTAB mechanisms. There was, as we all learned recently thanks to the federal circuit case last week, there's certainly no discovery in inter partes reexamination. And that was pointed out by Congress, that patent owners, in particular, wanted to challenge some of these declarations ...

Recorded on: Apr. 3, 2013

ROB STERNE: And we're very, very fortunate to have Dave Kappos, who recently stepped down from being our director at the PTO. I was at the PTO yesterday for a reexam interview with Deborah Jones and Art Unit 3991, and mentioned that Dave was going to be on our program today. And everyone in the room at the PTO, as well as the people at the guard desks and everywhere else, have only the nicest things to say about our speaker. Dave, you should know ...

Recorded on: Apr. 3, 2013

ROBERT GREENE STERNE: Well, welcome again, and now we're going to be addressing the very important subject of appeals from the Board to the Federal Circuit, something that I think a lot of us are woefully deficient in our appreciation of the task at hand, and we need to get up to speed on this very important piece of the puzzle. So as we start this panel discussion, first of all, let me introduce John Dragseth, who is our other faculty member, in ...

Recorded on: Apr. 3, 2013

SCOTT MCKEOWN: Welcome back, everybody. We're ready to kick off the afternoon session. But before we do, we did have one question that came in late. And that question was, must an IPR petition be accompanied by an expert declaration? For example, the questioner wants to know if you have clear disclosures in the prior art, maybe you can just come in without the declaration. The short answer is of course there's no requirement that you file a declaration. ...

Recorded on: Apr. 2, 2013

DANIEL L. REISNER: It's my pleasure to introduce the speakers for our last topic today. Grace Pan is a partner at Kay Scholer in our New York office. She is a graduate of Northwestern University School of Law, where she graduated Phi Delta Phi and Iota Sigma Phi. Grace speaks Chinese and Japanese, travels often to Asia, and represents numerous Asian clients with intellectual property and commercial issues. Grace is a member of numerous professional ...

Recorded on: Apr. 2, 2013

DAVID K. BARR: Switch to our second topic which is biologic and biosimilar drug products. And I'm fortunate to have with me sharing this topic, Betty Ryberg. And introducing Betty Ryberg, she joined Novartis in 2008 as vice president of US IP litigation for group intellectual property. And she leads Novartis Corporation's IP group. Before joining Novartis, Betty was a colleague of ours at Kaye Scholer. And she worked on numerous pharmaceutical biotech ...

Recorded on: Apr. 2, 2013

DAVID BARR: Everyone just a brief change in our schedule. We're going to be going forward with the in-house panel on pharma and biotech litigation for the 3:00 slot. And the panel on biotech and pharma licensing in Asia will take place at 4:00. So same subject matter, just flipping those two panels. So we're pleased and privileged to have today with us three in-house counsel to discuss a lot of the issues-- maybe in more depth than we were discussing ...

Recorded on: Apr. 2, 2013

DANIEL L. REISNER: Morning, everyone. I'm going to start with the first topic of the day, which is claim construction. Judge Holderman, about five years ago, wrote, something has to change when your boss, upon reviewing your work, continues to tell you, year after year, that you are doing your job incorrectly about 1/3 to 1/2 of the time, and your customers continue to tell you their costs are too high. Judge Holderman was speaking about the Federal ...

Recorded on: Apr. 2, 2013

DANIEL REISNER: I'd like to introduce our next speaker, Steve Elliott. He has an undergraduate degree in chemical engineering from MIT. He was then a process and materials engineer for Intel Corporation, where he developed integrated circuit manufacturing technology. Now Steve is a special counsel at Sullivan & Cromwell, where he represents clients in a wide range of technologies, including pharmaceuticals, medical devices, biotechnology, and ...

Recorded on: Apr. 2, 2013

DAVID BARR: Good afternoon everyone. Welcome back for the afternoon session of our conference. And I'm pleased to introduce Joe Drayton from Cooley, who's going to be speaking about the American Invents Act, post-grant procedures under the AIA. Joe Drayton is a partner in Cooley's litigation department. And he's a member of their intellectual property litigation practice group. He joined Cooley in 2012. And he's a resident in Cooley's New York office. ...

Recorded on: Mar. 20, 2013

SCOTT ALTER: So to keep things on time, we're gonna go ahead and get started. This is the corporate counsel panel also known as what keeps corporate in-house counsel up at night. And for that we have some outstanding corporate counsel to talk about these issues with us. Too close. Stay a little bit away from the microphone, I'm told here. Our first panelist is T. J. Angioletti who is Associate General Counsel, Technology Transactions for Netflix. ...

Recorded on: Mar. 20, 2013

SCOTT ATLER: All right. We're gonna go right into the next session which is gonna be hot topics in technology transfer. We have a couple of great speakers to talk to us about this topic today. The first is Cheryl-- CHERYL FRAGIADAKIS: Thank you. SCOTT ATLER: --Fragiadakis who is head of technology transfer and intellectual property management at the Lawrence Berkeley National Laboratory. That lab is the oldest US national laboratory operated for ...

Recorded on: Mar. 20, 2013

DOUGLAS NEMEC: Welcome back, everybody. We'll get started with the first plenary session of the day. We're going to spend the next hour talking about litigation involving non-practicing entities, or patent-assertion entities, or patent trolls-- whatever term you prefer. When I started practicing-- it really wasn't all that long ago, in the 1990s-- these terms really didn't exist. Patent troll was a really unattractive patent lawyer, and a non-practicing ...

Recorded on: Mar. 20, 2013

JOHN WHITE: Hello, welcome back. It's time for our last hour together. That's right, we're here. I know, sadness, because it's almost over. And there's nothing like two days of patent fun bringing us all together. So I have a few things. Number one, thank you all for coming. And the thing we want back from you are your evaluations. This can be accomplished on those iPads in front of you. And there are two tabs, one for faculty and one for content. ...

Recorded on: Mar. 20, 2013

SPEAKER 1: OK, we're going to go ahead and get restarted. Welcome back, everyone. We are here at the Patent Markets panel. A lot has been happening, as most of you know, with relation to patents, and buying and selling and brokering of them, as of late. We're fortunate to have several people here today, very knowledgeable this area, to talk to us about some of these issues. To my immediate right, your left, is Kevin Barhydt, who is Vice President ...

Recorded on: Mar. 19, 2013

[? DOUGLAS R. NEMEC: Brian ?] managed to cover about 800 pages of Federal Register reports on Patent Office rule-making. We'll now turn it over to Denise De Mory to cover 800 or more pages of court decisions from the last year from Supreme Court, Federal Circuit, and other courts. You've got a challenge on your hands there. Denise is a founding partner at Bunsow, De Mory, Smith, and Allison in Silicon Valley. She's got about 20 years of experience ...

Recorded on: Mar. 19, 2013

DOUGLAS R. NEMEC: So we'll moving into developments in pharmaceutical and biotech patent litigation, a topic that's of interest, I think, to a narrower group of the audience than perhaps some that we've been covering. But to those of us who practice in that area, it's an area of great interest and one where there's really a lot going on in recent months and recent years. I'm happy to turn the program over to Asim Bhansali, who's a partner at Keker ...